• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

SGLT2 inhibitor canagliflozin alleviates vascular calcification through suppression of NLRP3 inflammasome
CONCLUSIONS: Our study for the first time demonstrates that CANA exerts a protective effect on vascular calcification at least partially via suppressing NLRP3 signaling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for vascular calcification.PMID:37523743 | DOI:10.1093/cvr/cvad119
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: An Chen Zirong Lan Li Li Luting Xie Xiaoyu Liu Xiulin Yang Siyi Wang Qingchun Liang Qianqian Dong Liyun Feng Yining Li Yuanzhi Ye Mingwei Fu Lihe Lu Jianyun Yan Source Type: research

Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
ConclusionCana conveys anti-inflammatory actions in LPS-treated HCAECs through 1) reductions in HKII and ERK1/2 phosphorylation and 2) AMPK activation. These data suggest a novel anti-inflammatory mechanism of Cana through HKII.
Source: Cardiovascular Drugs and Therapy - December 1, 2021 Category: Cardiology Source Type: research

NRF2 in Cardiovascular Diseases: a Ray of Hope!
AbstractHeart failure is a worldwide pandemic influencing 26 million individuals worldwide and is expanding. Imbalanced redox homeostasis in cardiac cells alters the structure and function of the cells, which leads to contractile dysfunction, myocardial hypertrophy, and fibrosis in chronic heart failure. Various targets and agents acting on these such as siRNA, miRNA, interleukin-1, opioids, vasodilators, and SGLT2 inhibitors are being evaluated for heart failure, and nuclear factor erythroid 2 –related factor 2 (NRF2) is one of them. NRF2 is a master transcription factor which is expressed in most of the tissues and exh...
Source: Journal of Cardiovascular Translational Research - November 25, 2020 Category: Cardiology Source Type: research

Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
ConclusionCana conveys anti-inflammatory actions in LPS-treated HCAECs through 1) reductions in HKII and ERK1/2 phosphorylation and 2) AMPK activation. These data suggest a novel anti-inflammatory mechanism of Cana through HKII.
Source: Cardiovascular Drugs and Therapy - October 13, 2020 Category: Cardiology Source Type: research